DIRS.INFO The most relevant business & tech news

☆ Why the biggest real estate funds still struggle
▼ + stars: | 2024-05-17 | by ( Daniel Geiger | ) www.businessinsider.com time to read: +8 min

Read previewBlackstone, the world's largest landlord, contends the worst is over for commercial real estate. In the first quarter, shareholders in Blackstone Real Estate Income Trust, or BREIT, its $59 billion flagship real estate investment fund, pulled out almost a billion dollars a month on average, according to the company's first-quarter earnings statement. A similar investment fund operated by Barry Sternlicht's Starwood Capital has had an even greater retreat by investors. Share pricing is determined through appraisals of the value of the underlying real estate holdings. In May, Blackstone Real Estate Partners X also completed the $3.5 billion acquisition of Tricon Residential, an owner of single family rental homes.

Persons: —, Barry Sternlicht's, Kevin Gannon, BREIT, reinvigorating, anemic, REITs, Jonathan Gray, Blackstone Heidi Gutman, NBCUniversal, Jon Gray, they're, Gray, outperformance, redemptions, Blackstone, Gannon, They're, Sternlicht, Todd Henderson, REIT, Henderson, It'll Organizations: Service, Investors, Income Trust, Business, Barry Sternlicht's Starwood Capital, Starwood Real, Blackstone, Starwood, KKR, Apollo, Federal Reserve, Communities, Blackstone Real Estate Partners, Tricon Locations: Blackstone, Brookfield, BREIT, Tricon, Nashville, DWS

☆ Cramer's Lightning Round: 'I'm a believer' in Moderna
▼ + stars: | 2024-05-14 | by ( Julie Coleman | ) www.cnbc.com time to read: 1 min

MindMed : "I like MindMed...Anything that makes it so that there's ways to be able to get rid of pain and do good without getting people hooked, I am all in on. Doesn't necessarily mean it will make a lot of money, I don't care. I think that people have to recognize this is an unmet need, and it will make money in the end."

☆ Gov. Jim Justice Faces Heavy Business Debts as He Seeks Senate Seat
▼ + stars: | 2024-05-12 | by ( Campbell Robertson | Maureen Farrell | ) www.nytimes.com time to read: +1 min

Jim Justice, the businessman-turned-politician governor of West Virginia, has been pursued in court for years by banks, governments, business partners and former employees for millions of dollars in unmet obligations. And for a long time, Mr. Justice and his family’s companies have managed to stave off one threat after another with wily legal tactics notably at odds with the aw-shucks persona that has endeared him to so many West Virginians. But now, as he wraps up his second term as governor and campaigns for a seat in the U.S. Senate, things are looking dicier. Much like Donald J. Trump, with whom he is often compared — with whom he often compares himself — Mr. Justice has faced a barrage of costly judgments and legal setbacks. And this time, there may be too many, some suspect, for Mr. Justice, 73, and his family to fend them all off.

Persons: Jim Justice, Joe Manchin III, Donald J, — Mr, Justice Organizations: West Virginians, Republican Senate, Democratic, U.S . Senate, Trump Locations: West Virginia, West, U.S

☆ The 9 types of unhealthy friendships — and when to leave each one
▼ + stars: | 2024-05-06 | by ( Julia Pugachevsky | ) www.businessinsider.com time to read: +7 min

Author Danielle Bayard Jackson shared 9 types of "bad" friends — and how to deal with each one. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementIn her forthcoming book "Fighting for Our Friendships" (out on May 7), Jackson discusses nine types of "bad" female friends she's heard her coaching clients complain about. The non-reciprocal friendThis friend makes you feel like you're in a one-sided relationship. Jackson said it's a good idea to leave if the friend consistently makes you feel like a social placeholder during their single seasons.

Persons: Danielle Bayard Jackson, —, it's, Jackson, she's, you've, they're Organizations: Service

☆ Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
▼ + stars: | 2024-05-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly , lower on Friday. Eli Lilly shares dropped nearly 3%, while Novo Nordisk's U.S.-traded shares fell more than 1%. Still, investors were pleased with Eli Lilly on Tuesday after the company assured them it can overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year. That signals Novo Nordisk is struggling to meet demand for the treatment.

Persons: Amgen, Eli Lilly, Bob Bradway, Bradway, Jay Bradner, autoinjector, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, William Blair, Matt Phipps, Michael Yee, Amgen's Bradway, Karsten Munk Knudsen Organizations: Novo Nordisk, Novo Nordisk's, Jefferies, MariTide, Nordisk Locations: Novo Nordisk's U.S, North Carolina, Indiana, Ireland, Germany, U.S

☆ Winners and Losers of the Columbia Protests? History Will Tell.
▼ + stars: | 2024-05-03 | by ( Ginia Bellafante | ) www.nytimes.com time to read: +3 min

Two years later, a plurality of Americans held the view that so-called outside agitators — in this instance, Communists — were behind the civil rights movement. If we think of attention as a prevailing measure of success, then the Columbia protests, inspiring so many others and consuming global headlines, have been triumphant. “I see very little talk this week about what is happening to Palestinians in Gaza,” Peter Staley, the celebrated AIDS activist, told me. He recalled a major ACT UP demonstration in December 1989 at St. Patrick’s Cathedral that is still debated among participants. The idea was to disrupt a Mass offered by Cardinal John O’Connor to condemn the church’s stance on condoms.

Persons: Eric Adams, ”, condescension, —, unmet, ” Peter Staley, Cardinal John O’Connor, ” Mr, Staley Organizations: Columbia University, Hamilton Hall, Gallup, Washington, Police Department, ACT Locations: Gaza, Columbia, Morningside Heights, St, Patrick’s

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ Starbucks gets a price target cut after a brutal quarterly miss and light guidance
▼ + stars: | 2024-04-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +8 min

In Starbucks' international segment, comparable store sales fell 6% and missed estimates of 0.5% growth. The street was looking for flat comparable sales in China, according to FactSet. China comparable sales are expected to decline by a single-digit percentage versus expectations of low single-digit growth in the second quarter through the fourth quarter. Global net new store growth was tweaked down from 6% to 7%. That's due to slower China store openings, which was revised to 12% growth from 13%.

Persons: Laxman Narasimhan, Dunkin, Jim Cramer's, Jim Cramer, Jim, Spencer Platt Organizations: Revenue, Starbucks, Bros, McDonalds, Wall Street, Global, CNBC, Getty Locations: China, United States, North America, Latin America, Asia, Japan, Manhattan , New York City

☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.

Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S

☆ This biotech stock specializing in targeted cancer treatments can surge 50%, Jefferies says
▼ + stars: | 2024-04-17 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Nuvalent could be a winning biotech in the world of cancer treatments, according to Jefferies. Analyst Roger Song initiated the clinical-stage biopharmaceutical company with a buy rating and $97 price target, which implies 49.8% potential upside for shares over the next 12 months. "NUVL leverages strong expertise in structure-based chemistry and deep understanding of unmet [patient] needs to develop potentially 'best-in-class' small molecule targeted cancer therapy," Song wrote in a Wednesday note. "We think both candidates poise well in later line and have strong potential to move into frontline treatments." The company posted a fourth-quarter loss that was slightly wider than expected, at 62 cents per share.

Persons: Roger Song, Jefferies Organizations: Jefferies, U.S . Food, Drug Administration, FactSet Locations: U.S

☆ Here are Wednesday's biggest analyst calls: Nvidia, Broadcom, Apple, Tesla, Netflix, Amazon, Microsoft & more
▼ + stars: | 2024-04-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Wednesday's biggest calls on Wall Street: Barclays reiterates Tesla as equal weight Barclays lowered its price target on Tesla to $180 per share from $225 and said it sees a negative catalyst heading into earnings. Wells Fargo reiterates Microsoft as overweight Wells raised its price target on the stock to $480 per share from $460. Barclays reiterates Broadcom as overweight Barclays raised its price target on Broadcom to $1,500 per share from $1,405. Wells Fargo reiterates Goldman Sachs as overweight Wells said it gives a "gold star" to Goldman coming out of earnings. Truist reiterates Amazon as buy Truist raised its price target on the stock to $216 per share from $195.

Persons: Tesla, Mizuho, RCL, Hancock Whitney, Raymond James, it's, Vernova, Wells, AAPL, TD Cowen, Jefferies, Morgan Stanley, NVDA, Goldman Sachs, Goldman, Maxim, Truist Organizations: Street, Barclays, Royal Caribbean, Citi, GE, HSBC, Biotech, Apple, Microsoft, Broadcom, Education, Strategic Education, Guggenheim, Automotive, Netflix Locations: China, Gulf

☆ Bull market breaks its stride with the S&P 500's first 2% dip in a long while
▼ + stars: | 2024-04-06 | by ( Michael Santoli | ) www.cnbc.com time to read: +8 min

Was that a change in the market's character last week, or is it still the same old bull? This is generally to the good, as boring markets are bullish markets while they remain that way. Rates and commodities worries Other asset markets have also been at least inviting the question about a potential shift in character. The good news on this, as I keep insisting, is that it hasn't been a truly Fed-driven market. Though it's easy to imagine the market chafing at this kind of higher-rate, higher-growth equilibrium if it continues too much longer.

Persons: Ned Davis, Jerome Powell, hasn't, That's, We're, It's, Andrew Kelly Organizations: Ned Davis Research, Treasury, Fed, Investors Intelligence, Investment, Deutsche Bank ., New York Stock Exchange Locations: New York City, U.S

☆ CPAP replacement works well for the overweight, not obese, study finds
▼ + stars: | 2024-04-04 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +9 min

CNN —An implant for obstructive sleep apnea — a serious sleep malady in which breathing stops for 10 seconds to two minutes many times an hour each night — works best in people who are overweight but not severely obese, a new study found. “There’s a huge unmet need of patients that are suffering with obstructive sleep apnea and not able to tolerate CPAP,” Landsness said. nicolesy/iStockphoto/Getty ImagesAbout a third of patients have difficulty using a CPAP and may ultimately abandon the device, Landsness said. Obstructive sleep apnea is also connected to type 2 diabetes, asthma, obesity, kidney disease, chronic obstructive pulmonary disease, thyroid disease and mental illnesses such as depression and anxiety. “As an alternative treatment for sleep apnea, this hypoglossal nerve stimulation surgery could revolutionize some people’s lives,” he said.

Persons: Eric Landsness, St . Louis, ” Landsness, ”, Kristen Knutson, “, Landsness, CPAP, Brandon Peters, Mathews, ” Peters, Raj Dasgupta, Dasgupta, “ I’ve Organizations: CNN, Washington University School of Medicine, Medicare, BMI, Northwestern University’s Feinberg School of Medicine, Virginia Mason Medical Center, Food and Drug Administration, Huntington Health, Mayo Clinic, telltale Locations: St ., Chicago, Seattle, Pasadena , California

☆ Why this market has left behind direct-to-consumer companies like Warby Parker, AllBirds and Rent the Runway
▼ + stars: | 2024-04-03 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +7 min

Direct-to-consumer brands – household names like HelloFresh, Peloton, Allbirds, Stitch Fix, Warby Parker and Rent the Runway, which cut out traditional retailers, wholesalers and other middlemen – have been falling. Investors shied away from high-growth stocks and retreated into companies with solid fundamentals and, most importantly, lots of profit. The problem is that none of these direct-to-consumer (DTC) companies have managed to make the transition to profitability themselves. Rent the Runway was down $114 million, and mattress company Purple lost about $121 million. Other companies, like SmileDirectClub, which went public in 2019, and Winc, a wine subscription company that went public in 2021, have declared bankruptcy.

Persons: Allbirds, Warby Parker, don’t, they’ll, ”, Ben Cogan, they’ve, Cogan, Casper, “, it’s, Sesame, Michael Botta, Tesla, Chris Isidore, Elon Organizations: New, New York CNN, Agora, CNN, Hubble, Venture, “, Companies, Wonder Group, Durational Capital Management, Costco, Western, Tesla Locations: New York

☆ You can now get Ozempic at Costco — but don't expect big savings
▼ + stars: | 2024-04-03 | by ( Alex Bitter | ) www.businessinsider.com time to read: +3 min

Costco is now selling the weight loss drug Ozempic through a partnership with health startup Sesame. Still, that doesn't cover the cost of the GLP-1 drug, which has gained popularity but can be costly. Now, you can get a prescription for the weight loss drug Ozempic through the retailer, too. For $179, members can get a prescription for the GLP-1 weight loss drug plus a meeting with a doctor or specialist. Ozempic, Wegovy, and other GLP-1 drugs have gained popularity among people trying to lose weight over the last few years.

Persons: —, Michael DiLorenzo, DiLorenzo, Sesame, weren't, Michael Botta Organizations: Costco, Service, CNN, Business, Sesame, Novo Nordisk Locations: Denmark

☆ Tuition now costs a whopping $90,000 a year or more at some US universities
▼ + stars: | 2024-04-01 | by ( Madeline Berg | ) www.businessinsider.com time to read: +4 min

Some American universities estimate their total cost of attendance will exceed $90,000 next year. Tuition and fees at universities have continued to climb, even when adjusted for inflation. The result may be a generation of students wondering if college is worth it. AdvertisementThe price of getting a degree has continued to climb at American universities, with the cost of some schools reaching a new threshold. Out-of-state and in-state tuition and fees at public universities have risen by about 38% and 56%, adjusted for inflation, over the same period.

Persons: —, Gen, Ana Hernández Kent, Louis Organizations: Service, New York University, Tufts, University of Pennsylvania, Yale, NYU, Board, U.S . News, for Higher, of Education, Universities, Institute for Higher Education, Institute for Economic Equity, Federal Reserve Bank of St Locations: U.S

☆ Here are Monday's biggest analyst calls: Nvidia, Tesla, Delta, Skechers, Apple, Disney, Micron, Citi, Amazon & more
▼ + stars: | 2024-04-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley initiates Compass Pathways at overweight Morgan Stanley said in its initiation of Compass that it's bullish on shares of the mental health biopharma company. Morgan Stanley reiterates Taiwan Semiconductor as overweight Morgan Stanley said it's standing by its overweight rating on shares of TSM. Morgan Stanley reiterates Delta as a top pick Morgan Stanley said Delta's push into "premium" will reward investors. Bank of America reiterates Micron as buy Bank of America said it sees further share gains for Micron. Morgan Stanley reiterates Planet Fitness as overweight Morgan Stanley said it's standing by its overweight rating on the fitness company.

Persons: Jefferies, Goldman Sachs, Goldman, it's, it's bullish, Hunt, Werner, Robinson, Morgan Stanley, Delta, Wells, Evercore, Bill, Tesla, Oppenheimer, Sweetgreen, Baird downgrades, Baird, Tommy Bahama Organizations: Microsoft, Barclays, Barclays downgrades J.B, J.B, C.H, Taiwan Semiconductor, DAL, " Bank of America, Nvidia, Broadcom, Bank of America, Micron, Devon Energy, Bloom Energy, Energy, Disney, underperform Bank of America, Baird downgrades Fifth, Bancorp, Royal Caribbean, Citi, Citigroup Inc, Royal Caribbean Cruises Ltd, TPG Inc, TPG, TE Connectivity, Chevron Corp, Citi downgrades Oxford Industries Locations: TSM, Wells Fargo, Devon, F1Q, Cincinnati, Royal, Oxford

☆ A degree now costs more than $90,000 a year at some US universities, showing how wildly expensive education is getting
▼ + stars: | 2024-03-30 | by ( Madeline Berg | ) www.businessinsider.com time to read: +4 min

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewThe price of getting a degree has continued to climb at American universities, with the cost of some schools reaching a new threshold. This story is available exclusively to Business Insider subscribers. Out-of-state and in-state tuition and fees at public universities have risen about 38% and 56%, respectively, inflation-adjusted over the same period. In a Business Insider and YouGov survey conducted last year, 46% of Gen Z respondents said they don't think college is worth the cost.

Persons: —, Gen, Ana Hernández Kent, Louis Organizations: Service, New York University, Tufts, University of Pennsylvania, Yale, Business, NYU, Board, U.S News, of Higher, of Education, Universities, Institute of Higher, Institute for Economic Equity, Federal Reserve Bank of St

☆ Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
▼ + stars: | 2024-03-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna has more to offer beyond its Covid vaccine. The update brings Moderna a step closer to having multiple products on the market, which it badly needs amid plunging demand for Covid shots worldwide. Moderna will chart its post-Covid future Wednesday during its fifth annual "Vaccines Day," an investor event in Boston focused on the company's vaccine portfolio. That includes its combination vaccine against Covid and the flu and a shot against another common herpes virus called cytomegalovirus, or CMV. It also includes a new and improved version of Moderna's Covid shot.

Persons: norovirus, Barr, Moderna, Blackstone, Stéphane Bancel Organizations: Moderna, Epstein, Covid, Blackstone Life Sciences, Blackstone Group Locations: Boston, U.S

☆ This biotech startup is finding new cancer drugs with $75 million from General Catalyst. Here's the pitch deck Georgiamune used to raise its Series A.
▼ + stars: | 2024-03-26 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

Then, at the Georgia Cancer Center at Augusta University, he began the research that would eventually spin off into his first startup, Georgiamune. The same month, Georgiamune also got FDA clearance to begin human clinical trials for its first cancer drug candidate. Georgiamune's primary drug target works to solve a problem posed by another type of cancer drug on the market, called checkpoint inhibitors. For a Series A biotech startup, Georgiamune has an unusually extensive pipeline, with nine biological targets identified internally, all of which use different mechanisms of action than existing drugs. AdvertisementHere's the 21-slide pitch deck Georgiamune used to raise a $75 million Series A co-led by General Catalyst.

Persons: —, Samir Khleif, King, Khleif, Catalyst, CJNV BioVenture, Georgiamune, doesn't, Amy Abernethy, Khleif's, General Catalyst Organizations: Service, King Hussein Cancer Center, Georgia Cancer Center, Augusta University, Business, Parker Institute for Cancer, Mubadala, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Bicara Therapeutics, Therapeutics, General Locations: Jordan, Verily

Still, we're here to guide our children in a compassionate way through difficult moments at all stages of development. As child psychologists, we've developed an acronym that can assist us all through this process, regardless of our child's age: H.E.L.P. Whatever their action, before you react, it's smart to stop and ask yourself: Where is their behavior coming from? An underdeveloped thinking brain, an overactive emotional brain, and a lack of perspective leads to chaos and poor decision-making. Or is my reaction a reasonable response to my child's behavior, like if my child yelled "I hate you," and my feelings are hurt?

Persons: we've, Lean

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
▼ + stars: | 2024-03-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration on Thursday approved the first-ever treatment for a common and potentially deadly form of liver disease that affects millions worldwide. Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH. Madrigal's drug, which will be marketed as Rezdiffra, is specifically approved to treat patients with NASH who also have moderate-to-advanced liver scarring. NASH is a serious form of liver disease characterized by excess fat buildup and inflammation in the liver and can lead to liver scarring, also known as fibrosis, along with liver failure and liver cancer. Roughly 6 million to 8 million people in the U.S. have NASH with moderate-to-advanced liver scarring, according to an estimate cited by the FDA.

Persons: Madrigal, Eli Lilly, NASH, Nikolay Nikolov, Rezdiffra Organizations: Madrigal Pharmaceuticals, Drug Administration, Pharmaceuticals, Novo Nordisk, FDA, Immunology Locations: U.S

Amylyx said Friday it would discuss its plans for Relyvrio with patients and the FDA, which “may include voluntarily withdrawing” the drug. The latest company study showed that the drug did not slow the disease compared with a dummy treatment. Amylyx’s medication is part of a string of drugs for deadly, degenerative diseases that have won FDA approval in recent years despite questionable proof that they work. That commitment seemed to reassure FDA's advisers who voted in favor of the drug's approval, despite the questionable data. In the months before the decision the FDA faced intense pressure from ALS patients, advocates and members of Congress.

Persons: Lou Gehrig’s, Amylyx, ”, “, Relyvrio Organizations: WASHINGTON, Drug Administration, Amylyx Pharmaceuticals, Relyvrio, FDA, Cambridge, Amylyx Pharmaceuticals Inc, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S

☆ Single dose of LSD provides immediate, lasting anxiety relief, study says
▼ + stars: | 2024-03-07 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

CNN —A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday. Generalized anxiety order is characterized by excessive, ongoing thoughts that are difficult to control and interfere with day-to-day activities. Anxiety is one of the most common mental disorders in the US, according to the Anxiety and Depression Association of America. The MM120 study, however, was accomplished without the use of psychotherapy during the session. So that’s a critical difference.”Most adverse effects in the study were rated as mild to moderate by participants, occurring mostly on the day of the study, Karlin said.

Persons: “, ”, Daniel Karlin, MindMed’s MM120, ” Karlin, buspirone —, Karlin, David Nutt, Nutt, Dr, Gabriella Gobbi, Timothy Leary, Richard Alpert, Eddie Adams, Leary, Richard Nixon Organizations: CNN, US Food and Drug Administration, Medicine Inc, Tufts University School of Medicine, FDA, Depression Association of America, Unit, Imperial College London’s, McGill University Health Centre, Canada, Therapeutics, Mental Health, Harvard University, Harvard, League for Spiritual, Woodstock Locations: Boston, United States, Montreal, New York, Vietnam

Search resuls for: "unmet"

25 mentions found